Arthur He
Stock Analyst at HC Wainwright & Co.
(4.12)
# 517
Out of 5,124 analysts
46
Total ratings
51.02%
Success rate
17.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $120 → $135 | $42.97 | +214.17% | 5 | Dec 16, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $85 → $90 | $46.52 | +93.47% | 3 | Nov 10, 2025 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $1.82 | +284.62% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $15.44 | +10.10% | 1 | Jul 30, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.49 | +264.30% | 10 | Jun 17, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.70 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.43 | - | 8 | Mar 31, 2025 |
Nektar Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $42.97
Upside: +214.17%
Vera Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $85 → $90
Current: $46.52
Upside: +93.47%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.82
Upside: +284.62%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $15.44
Upside: +10.10%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.49
Upside: +264.30%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.70
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.43
Upside: -